The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

In addition, AstraZeneca, Daiichi Sankyo, and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent under the Temporary Access Process (pTAP). Together with the TLR, this ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated ... analysis using quantitative continuous scoring (QCS), AstraZeneca's proprietary computational pathology platform.

UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...